Search peptides, terms, sources/
Glossary

Off-Label Use

Using a licensed medicine for a purpose, population, route of administration or other condition of use that falls outside its officially approved indication. A regulator’s approval of a medicine for one use does not extend to other uses that have not been separately assessed. This site does not describe or recommend off-label use; where a regulator has commented on the risks of use outside a licensed indication, that caution is reported as part of the relevant peptide’s regulatory status.

Peptides where this matters

  • Semaglutide

    GLP-1 receptor agonist studied in type 2 diabetes, weight management and cardiovascular outcomes. UK prescription-only medicine; studied in large randomised trials.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongLicensed UK medicine
  • Tirzepatide

    Dual GIP and GLP-1 receptor agonist studied in type 2 diabetes and weight management. UK prescription-only medicine; studied in large randomised trials.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongLicensed UK medicine
  • Liraglutide

    Earlier-generation GLP-1 receptor agonist studied in type 2 diabetes and weight management. UK prescription-only medicine; licence status depends on the brand.

    Metabolic and incretinHuman trialsEvidence reviewed
    ModerateLicensed UK medicine

All glossary terms

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.